<DOC>
	<DOC>NCT01952574</DOC>
	<brief_summary>Randomized, double-blind, placebo-controlled, parallel-group, multi-center study followed by open-label phase. To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days</brief_summary>
	<brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention</brief_title>
	<detailed_description>Randomized, double-blind, placebo-controlled, parallel-group, multi-center study followed by open-label phase. Adults with a one-year history of episodic migraine and not receiving migraine prophylaxis medication will be randomized to one of three AMG 334 treatment groups or a placebo treatment group.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History of migraine for more than12 months prior to screening Migraine frequency: ≥ 4 and ≤ 14 migraine days per month in each of the 3 months prior to screening and during baseline phase Headache frequency: &lt; 15 headache days per month (with &gt; 50% of the headache days being migraine days) in each of the 3 months prior to screening and during baseline phase Demonstrated at least 80% compliance with the eDiary during baseline phase Older than 50 years of age at migraine onset History of cluster headache or basilar or hemiplegic migraine headache Unable to differentiate migraine from other headaches Failed &gt; 2 medication categories due to lack of efficacy for prophylactic treatment of migraine after an adequate therapeutic trial Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase Overuse of acute migraine medications in any month during the 3 months prior to screening or during screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>migraine, headache, prevention, prophylaxis</keyword>
</DOC>